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Abstract
Effective treatment of chronic pain with morphine is limited by decreases in the drug’s analgesic
action with chronic administration (antinociceptive tolerance). Because opioids are mainstays of
pain management, restoring their efficacy has great clinical importance. We have recently reported
that formation of peroxynitrite (ONOO−, PN) in the dorsal horn of the spinal cord plays a critical
role in the development of morphine antinociceptive tolerance and have further documented that
nitration and enzymatic inactivation of mitochondrial superoxide dismutase (MnSOD) at that site
provides a source for this nitroxidative species. We now report for the first time that
antinociceptive tolerance is also associated with the inactivation of MnSOD at supraspinal sites.
Inactivation of MnSOD led to nitroxidative stress as evidenced by increased levels of products of
oxidative DNA damage and activation of the nuclear factor poly (ADP-ribose) polymerase in
whole brain homogenates. Co-administration of morphine with potent Mn porphyrin-based
peroxynitrite scavengers, (MnTE-2-PyP5+ and MnTnHex-2-PyP5+) (1) restored the enzymatic
activity of MnSOD, (2) attenuated PN derived nitroxidative stress, and (3) blocked the
development of morphine induced antinociceptive tolerance. The more lipophilic analogue,
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MnTnHex-2-PyP5+ was able to cross the blood brain barrier at higher levels than its lipophylic
counterpart MnTE-2-PyP5+ and was about 30 fold more efficacious. Collectively, these data
suggest that peroxynitrite mediated enzymatic inactivation of supraspinal MnSOD provides a
source of nitroxidative stress, which in turn contributes to central sensitization associated with the
development of morphine antinociceptive tolerance. These results support our general contention
that PN-targeted therapeutics may have potential as adjuncts to opiates in pain management.
Keywords
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Introduction
Opiate/narcotic analgesics, typified by morphine sulfate, are the most effective treatments
for acute and chronic severe pain; but their clinical utility is often hampered by the
development of analgesic tolerance as well as by de novo painful hypersensitivity to
innocuous and noxious stimuli, phenomena observed in both animal and human studies
(Arner et al., 1988, Mao et al., 1995). With respect to morphine in particular, tolerance
necessitates escalating doses to achieve equivalent pain relief (Foley, 1995). This complex
pathophysiological cycle contributes to decreased quality of life in the growing population
of subjects with chronic pain because of oversedation, reduced physical activity, respiratory
depression, constipation, potential for addiction, and other side-effects (Foley, 1995).
Accordingly, there is major interest in new approaches to maintain opiate efficacy during
repetitive dosing for chronic pain, without engendering tolerance or unacceptable side-
effects. Our studies to date have shown that targeting peroxynitrite (ONOO−, PN) is an
effective therapeutic strategy in blocking the development of antinociceptive tolerance
(Salvemini, 2009, Salvemini and Neumann, 2009).
Spinal formation of PN, the reaction product between superoxide (O2·−) and nitric oxide
(·NO) (Beckman et al., 1990), is a potent proinflammatory reactive nitroxidative species
(Salvemini et al., 1998, Jagtap and Szabo, 2005). Since the rate of interaction between ·NO
and O2·− to form PN is faster than the dismutation of O2·− by SOD, the most critical roles of
O2·− and ·NO in pain and inflammation may be their formation of PN (Salvemini, 2009).
Indeed, PN has been recently implicated in the development of thermal hyperalgesia
associated with acute and chronic inflammation (Wang et al., 2004, Khattab, 2006, Bezerra
et al., 2007, Ndengele et al., 2008), in response to spinal activation of the N-methyl-D-
aspartate receptor (NMDAR) (Muscoli et al., 2004) and in the development of opiate
induced antinociceptive tolerance (Muscoli et al., 2007, Batinic-Haberle et al., 2009b,
Ndengele et al., 2009). Furthermore, the use of non-selective pharmacological probes (i.e.
these agents react not only with O2·− but also with several nitroxidative species and
derivatives thereov) (Muscoli et al., 2003) such as PBN [phenyl N-tert-butylnitrone (PBN)]
and TEMPOL [4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl] has supported the role of
nitroxidative stress (defined as stress caused by the presence of O2·−, ·NO and/or PN and
related derivatives) in both neurogenic nociception (Gao et al., 2007, Lee et al., 2007,
Schwartz et al., 2008, Schwartz et al., 2009), visceral pain (Wang et al., 2008) and
neuropathic pain (Tal, 1996, Park et al., 2006, Gao et al., 2007, Siniscalco et al., 2007).
Ultimately, selective PN decomposition catalysts should confirm the contribution of PN in
such settings.
It is well documented that inactivation of manganese superoxide dismutase (MnSOD), the
enzyme that normally keeps concentrations of O2·− under tight control (McCord and
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Fridovich, 1969) is a central source for O2·−-derived PN in many diseases driven by overt
production of PN (MacMillan-Crow and Thompson, 1999, MacMillan-Crow et al., 2001).
Such enzymatic inactivation results from nitration on Tyr-34 by PN in a Mn-catalysed
process (MacMillan-Crow and Thompson, 1999). We have recently extended these findings
to provide evidence that spinal inactivation of MnSOD is also a central source for the
formation of PN in the development of morphine antinociceptive tolerance (Muscoli et al.,
2007, Ndengele et al., 2009). Under these circumstances, increased spinal PN contributes to
antinociceptive tolerance through three well defined biochemical pathways within the dorsal
horn of the spinal cord: (1) post-translational nitration of proteins involved in glutamate
homeostasis such as glutamate transporters and glutamine synthase (2) neuroimmune
activation and (3) neuronal apoptosis (Muscoli et al., 2007, Batinic-Haberle et al., 2009b).
Whether PN-mediated nitroxidative stress at supraspinal sites contributes to the
development of morphine antinociceptive tolerance is not known. In this study we show that
the development of antinociceptive tolerance following chronic administration of morphine
was associated with supraspinal inactivation of MnSOD which provided a source for PN and
PN-mediated nitroxidative stress. The PN decomposition catalysts MnTE-2-PyP5+ and
MnTnHex-2-PyP5+ (Batinic-Haberle, 2002) potently blocked MnSOD nitration at
supraspinal sites and the development of antinociceptive tolerance with MnTnHex-2-PyP5+
being more potent than MnTE-2-PyP5+. These results suggest that in addition to the
documented spinal role of PN in tolerance (Muscoli et al., 2007, Batinic-Haberle et al.,
2009a, Ndengele et al., 2009), supraspinal PN has an important role as well.
Methods
Mn porphyrins
MnTE-2-PyP5+ and MnTnHex-2-PyP5+ were synthesized and characterized as previously
described (Batinic-Haberle, 2002).
Thin-layer chromatography
Thin-layer chromatography of the purified compounds was performed on plastic-backed
silica gel TLC plates with 1:1:8 KNO3-saturated H2O: H2O: acetonitrile mixture as mobile
phase. Typically, 1 µL of ~1 mM samples were applied at ~ 1cm of the strip border and the
solvent front was allowed to run ~12 cm. The absolute Rf values and their ratio thereoff are
sensitive to the degree of the saturation of vapor phase in the TLC chamber and may differ
slightly from one to another experiment. Thus, the internal standardization of TLC is
required for comparison purposes [Kos et al Free Radic Biol Med 2009]. For the purpose of
this study and given high levels of ascorbate in brain Mn(III) porphyrins and ascorbate-
reduced Mn(II) porphyrins (MnTE-2-PyP4+ and MnTnHex-2-PyP4+) were applied on silica
plates. Mn(II) porphyrins are less stable and may lose Mn to some extent. Consequently in
solution there may be some amount of metal-free porphyrins that bear same 4+ total charge
and may have similar adsorption on the silica as reduced Mn(II) porphyrins. Thus we
applied on TLC plates metal-free porphyrins, H2TE-2-PyP4+ and H2TnHex-2-PyP4+ as
controls also. The thin-layer chromatographic behavior/lipophilicity of Mn porphyrins was
described by retention factor, Rf which presents the ratio of Mn porphyrin path and solvent
path. Based on Rf values, the POW values were then calculated (see Results).
Induction of morphine-induced antinociceptive tolerance in mice
The development of morphine induced tolerance was performed as described (Muscoli et al.,
2007, Batinic-Haberle et al., 2009b, Ndengele et al., 2009). Male CD-1 mice (24–30g,
Charles River) were housed and cared for in accordance with the guidelines of the
Institutional Animal Care and Use Committee of the Saint Louis University Health Science
Center and in accordance with the National Institute of Health Guidelines on Laboratory
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Animal and the University of Messina, in compliance with Italian regulations on protection
of animals used for experimental and other scientific purposes (D.M. 116192) as well as
with the EEC regulations (O.J. of E.C. L 358/1 12/18/1986). Mice were housed 4–5 per
cage, maintained under identical conditions of temperature (21±1°C), humidity (60±5%)
with a 12-hr light-dark cycle, and allowed food ad libitum. Nociceptive/pain thresholds were
determined by measuring latencies (in seconds, s) of mice placed in a transparent glass
cylinder on a hot plate (Ugo Basile, Italy) maintained at 52°C. Responses indicative of
nociception included intermittent lifting and/or licking of the hindpaws or escape behavior.
Determination of antinociception/pain relief effects was assessed between 7:00 and 10:00
AM. All injections were given by intraperitoneal (ip) or subcutaneous (sc) means in a 0.1 ml
volume at approximately 7 AM and 4 PM. Drug or vehicle (saline) was given before each
dose of morphine. Hot plate latencies were taken in mice from all groups on day five before
(baseline latency) and 40 min after an acute dose of morphine (3 mg/kg) or its vehicle
(saline) (response latency). Baseline values from all groups as measured on day five before
injection of the acute dose of morphine or its vehicle, similarly ranged between 6–8 s.
Results are expressed as percent maximal possible antinociceptive effect (% MPE)
calculated as follows: (response latency − baseline latency)/(cut off latency − baseline
latency) × 100 (Muscoli et al., 2007). A cut-off latency of 20 s was employed to prevent
tissue damage. Twelve mice per group were used and all experiments were conducted with
the experimenters blinded to treatment conditions. Unless specified, all drugs were
purchased from Sigma. The following experimental groups were used.
Naïve group (N)—Mice were injected twice a day with an ip injection of saline and a sc
injection of saline. On day five, mice received an ip injection of saline followed fifteen
minutes later by a sc injection of saline.
Vehicle group (V)—Mice were injected twice a day with an ip injection of saline and a sc
injection of saline. On day five, mice received an ip injection of saline followed fifteen
minutes later by a sc injection of acute morphine eliciting near-to-maximal antinociception
(3 mg/kg) at 40 minutes after injection.
Tolerant group (T)—Mice were injected twice a day with an ip injection of saline and sc
injection of morphine (20 mg/kg/day). On day five, mice received an ip injection of saline
followed fifteen minutes later by a sc injection of acute morphine (3 mg/kg). Hot plate
latencies were taken 40 minutes after morphine injection.
Tolerant + drugs group—Mice were injected twice a day with an ip injection of varying
doses of MnTE-2-PyP5+ (0.3–3 mg/kg/day) or MnTnHex-2-PyP5+ (0.01–0.1 mg/kg/day)
followed by a sc injection of morphine (20 mg/kg/day). On day five, mice received an ip
injection of MnTE-2-PyP5+ (1.5 mg/kg/day) or MnTnHex-2-PyP5+ (0.05 mg/kg/day)
followed fifteen minutes later by the sc injection of acute morphine (3 mg/kg). Hot plate
latencies were taken 40 minutes after morphine injection.
After the behavioral tests on day five, whole brains were removed and tissues processed for
Western blot and biochemical analysis.
Western Blot
Whole brain lysates (n = 3 per group) were prepared as previously described (Wang et al.,
2004). Briefly, whole frozen brain (395–500 mg) were pulverized in liquid nitrogen-chilled
mortar and pestle prior to homogenization in 1.2 – 1.5 mL of lysis buffer [20 mM Tris-Cl
(pH 7.4), 150 mM NaCl, 16.2 mM CHAPS, 12.5 mM EGTA, 1% protease cocktail (Sigma,
St. Louis MO) (final concentration: 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride
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(AEBSF), 15 µM pepstatinA, 14 µM E-64, 40 µM bestatin, 20 µM leupeptin, and 850 nM
aprotinin), 10% glycerol]. The homogenates were sonicated for 10 min on ice in an
ultrasonic bath (VWR, Buffalo Grove IL), incubated an additional 10 min on ice, and
clarified by centrifugation for 10 min at 12500g, 4°C. The supernatants were frozen at
−80°C and the total protein content of an aliquot was measured by bicinchoninic acid assay
(Pierce, Rockford IL). The total lysates (40 µg) were denatured with an equal volume of
loading buffer (2X: 125 mM Tris-Cl (pH 6.8), 15 % glycerol, 3% SDS, 1.1 mM β-
mercaptoethanol, and 0.075% bromophenol blue) and heat denatured for 5 min at 95°C. The
total lysates were resolved by SDS-PAGE (170 V, ~55 min) with a 4–20% Tris-glycine
minigel (Lonza, Basile Switzerland) and electrophoretically transferred (100V, 1.5 h) to 0.2
µm nitrocellulose membrane (Whatman, Fordham Park NJ) in Towbin transfer buffer.
Additional transfers of total lysates serially diluted (2-fold) were prepared. The relative
levels of total MnSOD were determined by enhanced chemiluminescence (Wang et al.,
2004). Each membrane was blocked for 2 hr at RT (10% low-fat milk/PBS-T: 1X PBS,
0.05% Tween-20, and 0.1% thimerasol) and incubated for 1 hr at RT with a rabbit anti-
MnSOD monoclonal antibody (Millipore) diluted 1:1000 in 5% low-fat milk/PBS-T. The
membrane was washed 5 times in PBS-T (15 min and 4 × 5 min), then incubated with a goat
anti-rabbit IgG-HRP antibody diluted 1:10000 in 5% low-fat milk/PBS-T. After 5 washes in
PBS-T, the bands were visualized with Supersignal® West Femto chemiluminscence
substrate (Pierce) and captured on film (GE Healthcare, Piscataway NJ). The membranes
were subsequently washed twice with PBS-T for 10 min and equal loading was similarly
verified with a mouse anti-β-actin monoclonal antibody (Sigma, St. Louis MO) diluted
1:10000 and goat anti-mouse IgG-HRP antibody diluted 1:8000 in 5% low-fat milk/PBS-T.
The lack of species cross-reactivity of HRP-conjugated antibodies to the anti-MnSOD and
anti-β-actin was also confirmed. The densities of the MnSOD and β-actin bands were
quantified using ImageQuant 5.2 (GE Healthcare) and expressed as relative MnSOD:β-actin
densities.
Measurement of MnSOD and Cu,ZnSOD activities
Whole brain tissue was homogenized in a Polytron homogenizer in 4 – 5 ml of 10 mM
phosphate buffered saline, pH 7.2; then sonicated twice on ice for 20 s. The sonicated
samples were subsequently centrifuged at 1,100 g for 10–15 min and SOD activity was
measured in the supernatants (Wang et al., 2004). In brief, a competitive inhibition assay
was performed using xanthine-xanthine oxidase-generated superoxide to reduce nitroblue
tetrazolium (NBT) to blue tetrazolium salt. The reaction was performed in 50 mM carbonate
buffer, pH 10.1, containing 0.1 mM EDTA, 25 µM nitroblue tetrazolium, 0.1 mM xanthine
and 2 nM xanthine oxidase (Boehringer, Germany). The rate of NTB reduction was
monitored spectrophotometrically (Perkin Elmer, Lambda 5 Spectrophotometer, Milan,
Italy) at 560 nm. The amount of protein required to inhibit the rate of NBT reduction by
50% was defined as one unit of enzyme activity. Cu,ZnSOD activity was inhibited by
performing the assay in the presence of 2 mM NaCN after preincubation for 30 min.
Enzymatic activity was expressed in mU per µg of protein as previously described (Wang et
al., 2004).
Determination of 8-hydroxy-2'-deoxyguanosine (8-OHdG)
The isolation of DNA was performed as described previously by our group (Masini et al.,
2005). In brief, whole brain tissue was homogenized in 4 – 5 ml of 10 mM PBS, pH 7.4,
sonicated on ice 20 s twice, then 1 ml of 10 mM Tris-HCl buffer, pH 8, containing 10 mM
EDTA, 10 mM NaCl, and 0.5% sodium dodecyl sulphate was added. The lysates were
incubated for 1 h at 37°C with 20 µg/ml RNase I (Sigma-Aldrich, Milan, Italy) and then
overnight at 37 °C under argon in the presence of 100 µg/ml proteinase K (Sigma-Aldrich).
The DNA was extracted with chloroform/isoamyl alcohol (10/2 v/v), precipitated from the
Doyle et al. Page 5













aqueous phase with 0.2 volumes of 10 M ammonium acetate, solubilized in 200 µl of 20
mM acetate buffer, pH 5.3, and denatured at 90°C for 3 min. The extract was then
supplemented with 10 IU of P1 nuclease (Sigma-Aldrich) in 10 µl and incubated for 1 h at
37 °C with 5 IU of alkaline phosphatase (Sigma-Aldrich) in 0.4 M phosphate buffer, pH 8.8.
All of the procedures were performed in the dark under argon. The mixture was filtered by
an Amicon Micropure-EZ filter (Millipore Corporation, Billerica, MA), and 50 µl of each
sample was used for 8-hydroxy-2'-deoxyguanosine (8-OHdG) determination using a
Bioxytech enzyme immunoassay kit (Oxis, Portland, OR), per manufacturer’s protocol. The
values are expressed as nanogram of 8-OHdG per milligram of protein (Bradford, 1976).
Measurement of PARP Activity
PARP-1 activity was measured as described previously (Suzuki et al., 2004). Whole brain
tissue was gently homogenized at 4 °C, in 4 – 5 mL of 50 mM Tris HCI, pH 8, containing
0.1% tergitol-type NP-40 (NP-40), 200 mM KCI, 2 mM MgCl2, 50 µM ZnCl2, 2 mM
dithiothreitol (DTT) and protease inhibitors: 1 mM phenylmethylsulfonyl fluoride (PMSF),
5 µl/ml leupeptin, and antipain. Samples were then centrifuged and 10 µl of each
supernatant were incubated for 5 min at 25 °C with 2 µl of [3H]NAD+ (specific activity 25
Ci/mmol, G.E., Health Care, U.K.) in 50 mM Tris HCI, pH 8, containing 20 mM MgCl2, 1
mM DTT, and 20 µM NAD+ in the absence or presence of activated calf thymus DNA, in
the final volume of 100 µl. The reaction was stopped by the addition of 5% trichloroacetic
acid. Samples were filtered and the radioactivity in the acid-insoluble fraction was counted
by a Beckman LS1801 liquid scintillation spectrometer. PARP activity estimated without
activated DNA in the mixture was assigned as "endogenous" activity. Activity estimated in
the presence of activated DNA in the assay mixture was assigned as "total" activity of
PARP. Ratio between endogenous and total activity was considered as the measure of PARP
activity in the tissue. The values are expressed as pmol of NAD+ per µg of protein/h
(Bradford, 1976).
Statistics
For paired group analysis Students t-test were performed. For paired multiple groups,
analysis of variance followed by Student-Newman-Keuls test were employed to analyze the
data. Results are expressed as mean±s.e.m for n animals. A statistical significant difference
was defined as a P value <0.05.
Results
Lipophilicity of Mn porphyrins
The thin-layer chromatographic behavior of reduced Mn(II) porphyrins, MnTE-2-PyP4+ and
MnTnHEx-2-PyP4+, as described by retention factor Rf is given in Table 1. It is obvious that
reduced porphyrins are significantly more lipophilic than their oxidized Mn(III) analogues.
In brain due to the high level of ascorbate and their easy reducibility with ascorbate (Ferrer-
Sueta et al Chem Res Toxicol 1999, Batinic-Haberle et al, Free Radic Biol Med 2004), Mn
porphyrins will at least in part exist in reduced state which would further enhance their
accumulation. Utilizing POW vs Rf relationship (Kos et al., 2009) as given by equation, log
POW= 12.18 × Rf −7.43, we calculated the partition of both porphyrins between n-octanol
and water, POW. POW is a more common indicator of drug lipophilicity. Both Rf and POW
values are listed in Table 1.
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Inactivation of brain mitochondrial superoxide dismutase (MnSOD) as a source of PN in
the development of antinociceptive tolerance
When compared to mice treated over 4 days with saline, chronic administration of morphine
over the same time course led to the inactivation of MnSOD in whole brain homogenates as
evidenced by loss of the catalytic activity of this enzyme to dismute superoxide measured
spectrophotometrically on day 5 (n=12) (Fig. 2A). Chronic administration of morphine did
not change the total amount of MnSOD protein in brain homogenates as measured by
Western blotting analysis (Fig. 2B, C). The enzymatic activity of cytosolic SOD
(Cu,ZnSOD) was not affected (n=12) (Fig. 2D). Inactivation of brain MnSOD was
associated with the development of antinociceptive tolerance (Fig. 3A, B). When compared
to animals receiving an equivalent injection of its vehicle (Naïve group), acute injection of
morphine (3 mg/kg) in animals that received saline over four days (Vehicle group) produced
a significant and near-to-maximal antinociceptive response [percent maximal possible
antinociceptive effect (%MPE) ranging between 90–95%] (Fig. 3 A, B). On the other hand,
when compared to the antinociceptive response to acute morphine in animals that received
saline over four days, repeated administration of morphine over the same time course
(Tolerant group) led to the development of antinociceptive tolerance as evidenced by a
significant loss of its antinociceptive response (Fig. 3A, B). Baseline latencies in groups
treated with saline or morphine over four days before acute administration of morphine on
day five similarly ranged between 6–8 seconds (n=12).
Co-administration of morphine with varying doses of the PN scavengers MnTE-2-PyP5+
(0.3–3 mg/kg/day) or MnTnHex-2-PyP5+ (0.01–0.1 mg/kg/day) prevented the supraspinal
inactivation of MnSOD and restored its ability to enzymatically dismute superoxide (n=12)
(Fig. 2A) and blocked in a dose dependent fashion morphine antinociceptive tolerance [0.3–
3 mg/kg/day for MnTE-2-PyP5+ and 0.01–0.1 mg/kg/day for MnTnHex-2-PyP5+, n=12]
(Fig. 3A, B). We have previously demonstrated that MnTE-2-PyP5+ or MnTnHex-2-PyP5+
alone do not increase baseline latencies (Batinic-Haberle et al., 2009b).
The development of morphine-induced antinociceptive tolerance is associated with
supraspinal oxidative DNA damage and PARP activation: inhibition by MnTE-2-PyP5+ or
MnTnHex-2-PyP5+
It is now well established that inactivation of MnSOD increases superoxide levels thereby
favoring PN formation and thus increased nitroxidative stress (Yamakura et al., 1998,
MacMillan-Crow and Thompson, 1999, Macmillan-Crow and Cruthirds, 2001, MacMillan-
Crow et al., 2001, Yamakura et al., 2001). Here we show that the development of morphine
antinociceptive tolerance was associated with increased formation of nitroxidative stress
markers as measured in whole brain homogenates. Thus and as can be seen in Fig. 4, when
compared to mice treated over 4 days with saline, chronic administration of morphine over
the same time course increased 8OHdG (n=12, Fig. 4A), a marker of oxidative DNA
damage and increased the activation of PARP a nuclear enzyme known to be activated
following oxidative DNA damage (Fig. 4B). Co-administration of morphine with MnTE-2-
PyP5+ (3 mg/kg/day) or MnTnHex-2-PyP5+ (0.1 mg/kg/day) significantly reduced the
increased production of 8-OHdG (n=12) and significantly decreased PARP activity (Fig. 4A,
B).
Discussion
Mitochondrial superoxide dismutase (MnSOD), the enzyme that normally keeps
concentrations of superoxide under tight control (McCord and Fridovich, 1969) is an
exquisite and sensitive target for PN-mediated nitration and enzymatic inactivation
(MacMillan-Crow and Thompson, 1999). This process favors the accumulation of PN which
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in turn, nitrates and alters additional proteins and receptors, thereby perpetuating and
extending the initial damage (Radi et al., 2002). Over the years a great body of experimental
evidence has been gathered to link MnSOD inactivation as a source for PN and PN-driven
nitroxidative stress to several disease states (Macmillan-Crow and Cruthirds, 2001). More
recently, spinal inactivation of MnSOD has been linked to the development of peripheral
and central sensitization associated with inflammation and in the development of opiate-
induced antinociceptive tolerance (Muscoli et al., 2004, Wang et al., 2004, Muscoli et al.,
2007, Schwartz et al., 2008, Batinic-Haberle et al., 2009b, Ndengele et al., 2009, Schwartz
et al., 2009). The main objective of the study presented herein was to address whether in
addition to its spinal role (Muscoli et al., 2007, Batinic-Haberle et al., 2009b, Ndengele et
al., 2009), supraspinal inactivation of MnSOD, as a source of PN, contributes to the
development of morphine antinociceptive tolerance. Our results clearly show that the
development of antinociceptive tolerance was associated with enzymatic inactivation of
MnSOD in whole brain homogenates which in turn contributed to PN formation and PN-
mediated nitroxidative stress as evidenced by increased formation of 8-OHdG and increase
in PARP activity well know markers of the presence of severe nitroxidative stress. Inhibition
of PN with two PN scavengers (MnTE-2-PyP5+, MnTnHex-2-PyP5+) prevented MnSOD
inactivation and attenuated antinociceptive tolerance. The more lipophilic MnTnHex-2-
PyP5+ was found to be approximately 30-fold more potent a finding that can be explained at
least in part by the fact that MnTnHex-2-PyP5+ has better organ uptake (i.e brain). The
finding that the development of morphine-induced antinociceptive tolerance was not
associated with enzymatic inactivation of the cytosolic isoform of SOD, namely Cu,ZnSOD,
is consistent with previous studies that have shown that the interaction of Cu,ZnSOD with
PN does not affect the catalytic activity of the protein (Smith et al., 1992). Although little is
known about supraspinal locations and mechanisms of nitroxidative species in hyperalgesic
states, the rostral ventromedial medulla (RVM) may provide a point of origin for further
characterization of the roles of peroxynitrite during central sensitization.
Glutamate neurotransmission, in particular that mediated via activation of NMDAR and
glial cell activation in the RVM, contributes to central sensitization (see below). The µ-
opioid receptors, NMDA receptors, and glial cell activation in the RVM are all potential
sources for PN formation since each of these can release its precursors: O2·− and ·NO [see
(Watkins et al., 2007, Salvemini and Neumann, 2009) for reviews]. Furthermore, PN
contributes to NMDA-mediated central sensitization (Muscoli et al., 2004). Investigations
using intracerebroventricular injections of non-selective NOS inhibitor (Moore et al., 1991,
Kawabata et al., 1993, Salter et al., 1996, Zhao and Bhargava, 1996) or free radical
scavengers (Kim et al., 2004, Lee et al., 2007) attenuate central sensitization in various
animal models of hypersensitivity including opiate tolerance, implicating roles for
nitroxidative species at supraspinal sites. More specifically, RVM microinjections of NOS
inhibitors and NMDAR antagonists were all able to significantly reduce secondary
hyperalgesia following peripheral insult (Coutinho et al., 1998, 2001). Conversely, RVM
microinjections of ·NO donors or NMDA enhanced hyperalgesia (Urban et al., 1999, Guan
et al., 2002). Collectively these results suggest that supraspinal formation of nitroxidative
species formed upon activation of the NMDAR modulates central sensitization.
The homeostasis of extracellular glutamate, a primary endogenous ligand for the NMDAR,
is tightly regulated by sodium-dependent high-affinity glutamate transporters (GTs) in the
plasma membranes of both neurons and glial cells (Danbolt, 2001). Loss of the transport
function of these proteins leads to increased glutamate levels in the synaptic cleft,
overstimulation of NMDAR and neurotoxicity (Mennerick et al., 1999, Lievens et al., 2000).
In contradistinction to the key role of GTs, glutamine synthetase (GS) plays a pivotal role in
its intracellular metabolic fate by converting glutamate into nontoxic glutamine. Pertinent to
the context of our studies, is that PN nitrates and inactivates the transport activity of GTs
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and the enzymatic activity of GS (Trotti et al., 1996, Minana et al., 1997, Trotti et al., 1999,
Gorg et al., 2005). Furthermore, Zanelli and co-workers demonstrated that PN nitrates
tyrosine residues on NMDA receptor subunits, an event associated with constant
potentiation of synaptic currents, calcium influx, and ultimately increased NMDA-receptor
excitability and neuronal excitotoxicity (Zanelli et al., 2000, Zanelli et al., 2002). We have
recently shown that the development of opiate antinociceptive tolerance was associated with
nitration of GTs and GS (Muscoli et al., 2007) and of NMDAR (Salvemini, unpublished
observations) in dorsal horn tissues. Taken collectively and in an attempt to provide a
mechanism whereby PN formation at supraspinal sites modulates opiate tolerance, it is
possible that PN fosters tolerance via a pathway involving nitroxidative alterations of
glutamate homeostasis.
Spinal neuroimmune activation contributes to opiate antinociceptive tolerance [(Watkins et
al., 2007) (Salvemini and Neumann, 2009)for reviews] and inhibition of PN blocks spinal
glial cell activation and cytokine formation during antinociceptive tolerance (Muscoli et al.,
2007, Batinic-Haberle et al., 2009b, Ndengele et al., 2009, Salvemini and Neumann, 2009).
Since neuroimmune activation in the RVM has been associated with central sensitization
(Wei et al., 2008) we hypothesize that a second mechanism by which supraspinal PN fosters
tolerance is neuroimmune activation.
In summary, we have shown for the first time that supraspinal inactivation of MnSOD and
PN mediated nitroxidative stress plays a role in antinociceptive tolerance. We have further
shown that potent peroxynitrite scavengers, MnTE-2-PyP5+ and MnTnHex-2-PyP5+ were
able to prevent MnSOD inactivation and nitroxidative stress at that level thereby inhibiting
morphine tolerance. Investigations to determine the region of and cellular sources of
supraspinal PN will be important to determine neuroanatomical site of action during




%MPE percent maximal possible antinociceptive effect
Cu,ZnSOD copper/zinc superoxide dismutase
GS glutamine synthase
GT glutamate transporters
kcat and kred catalytic and reduction rate constants









ONOO− and PN peroxynitrite
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PARP poly(ADP-ribose) polymerase; PMSF
POW n-octanol/water partitioning constant
RVM rostral ventromedial medulla
SOD superoxide dismutase
E1/2 metal-centered reduction potential for Mn(III)P/Mn(II)P
redox couple




ration of Mn porphyrin path and solvent path on silica
plates
POW partition coefficient between n-octanol and water
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Structures of MnTE-2-PyP5+ and MnTnHex-2-PyP5+. Replacement of shorter ethyl with
longer hexyl side chains increases lipophilicity by several orders of magnitude (see Table 1).
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When compared to the vehicle group (V) repeated administration of morphine (tolerant
group, T) led to significant functional enzymatic inactivation of MnSOD (A) but not
Cu,ZnSOD (D) as evidenced by loss of its catalytic activity to dismute superoxide as
measured spectrophotometrically. Co-administration of morphine with MnTE-2-PyP5+ (3
mg/kg/day, n=12) or MnTnHex-2-PyP5+ (0.1 mg/kg/day, n=12) restored the enzymatic
activity of MnSOD. When compared to the vehicle group, repeated administration of
morphine did not change the total amount of MnSOD in whole brain tissue homogenates as
measured by Western blotting analysis. Gels shown in B are representative from gels
obtained in 3 animals. A composite of the densitometry data resulting from these
experiments is shown in C. *P<0.001 for Morphine alone vs Vehicle; †P<0.001 for
Morphine+drug-treated vs Morphine alone.
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Inhibition of morphine antinociceptive tolerance with MnTE-2-PyP5+ or MnTnHex-2-
PyP5+. On day five, acute injection of morphine (3 mg/kg) in animals that received saline
over four days produced a significant antinociceptive response when compared to responses
observed in animals that received an equivalent volume of saline (A, B, Vehicle, V vs Naïve,
N). On the other hand, a significant loss to the antinociceptive effect from the acute injection
of morphine was observed in animals that received repeated administration of morphine
over four days (tolerant group) (A, B). Co-administration of morphine over four days with
varying doses of MnTE-2-PyP5+ (0.3–3 mg/kg/day, n=12; A) or MnTnHex-2-PyP5+ (0.01–
0.1 mg/kg/day, n=12; B) inhibited the development of tolerance in a dose-dependent
manner. Results are expressed as mean ± s.e.m. for six animals. °P<0.001 for Vehicle, V vs
Naïve, N; *P<0.001 for Morphine alone vs Vehicle; †P<0.001 for Morphine + drug treated
vs Morphine alone.
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When compared to the vehicle group (V) repeated administration of morphine (tolerant
group, T) led to significant increase in dorsal horn tissue levels of 8OHdG (A) and
substantially activated PARP (B). These biochemical changes were significantly attenuated
by co-administration of morphine over four days with MnTE-2-PyP5+ (3 mg/kg/day, n=12)
or MnTnHex-2-PyP5+ (0.1 mg/kg/day, n=12) (A, B). Results are expressed as mean±s.e.m.
for twelve animals. *P<0.001 for Morphine alone vs Vehicle; †P<0.001 for Morphine +
drug-treated vs Morphine alone.
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